UNSPSC 51272603: Anileridine hydrochloride

This classification denotes an opioid receptor agonist and opioid with the molecular formula C22H28N2O2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 915Q054DLC, chemically known as 4-piperidinecarboxylic acid, 1-(2-(4-aminophenyl)ethyl)-4-phenyl-, ethyl ester, dihydrochloride but more generally known as anileridine hydrochloride, which bears US NIH Compound Identifier 31338. European Medicines Agency schedules Anileridine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00532MIG.

UNSPSC 51272603 Anileridine hydrochloride is a Commodity code that nominally names a single synthetic opioid active pharmaceutical ingredient, but the recent state and local opportunities posted under this code show little alignment with that specific substance. Instead, the opportunities reflect broader pharmaceutical procurement — naloxone (an opioid antagonist), generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription program design. The scope of work under this code as currently solicited spans public health supply acquisition (naloxone distribution systems), cooperative pharmaceutical contracting across state and local jurisdictions, and market intelligence gathering for state pharmacy benefit programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota and Oregon). The code does not show a consistent pattern of procurement tied to anileridine hydrochloride itself.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS) due July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract includes a two-year initial term with a one-year renewal option and requires E-Verify compliance, workers' compensation insurance, and commercial general liability coverage. The Texas Health and Human Services Commission released an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information about direct contracting capacity outside traditional pharmacy benefit manager and group purchasing organization channels. Minnesota's MMCAP released an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with products required in the marketplace by May 15, 2026, and resulting agreements effective July 1, 2026; evaluation weighs price competitiveness at 75 percent, fixed pricing at 10 percent, and compliance with cGMP and Drug Supply Chain Security Act requirements. The code shows limited recent procurement activity specifically tied to anileridine hydrochloride.